Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 18/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344412 | 0.92 | CCR9 (0.73) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL343922 | 0.88 | CCR9 (0.74) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL344136 | 0.85 | CCR9 (0.79) | CCR9 | |
| SCHEMBL11937069 | 0.85 | CCR9 (0.85) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL2629436 | 0.83 | CCR9 (0.84) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL343122 | 0.82 | CCR9 (0.75) | CCR9LMNAHTT | |
| SCHEMBL10251851 | 0.82 | CCR9 (0.62) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL11934697 | 0.82 | CCR9 (0.70) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL344931 | 0.82 | CCR9 (1.00) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL10285057 | 0.80 | CCR9 (0.75) | CCR9LMNAHTTTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270616-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC (US) | 2009-10-29 | — | — | US | disclosed |
| US-7582661-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090118307-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118307-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885LMNA 4484/4885HTT 2647/4885 |
| US-20090270616-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885LMNA 4484/4885HTT 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.